RIGEL PHARMACEUTICALS INC

Listed Company

RIGLCIK 0001034842NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$294.28M

Net Income

$367.02M

Total Assets

$513.59M

Equity

$391.48M

Shares Out

18.50M

Op. Cash Flow

$75.66M

RIGL$40.56+114.72% · past yearDBEQ Basic

Daily closing prices

Business

Rigel Pharmaceuticals is a biotechnology company developing and commercializing novel therapies for hematologic disorders and cancer. The company markets three FDA-approved products: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed/refractory acute myeloid leukemia with IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer and thyroid cancer. Rigel operates through direct US commercialization and international partnerships, with a clinical pipeline including R289 (IRAK1/4 inhibitor) and partnered programs with Eli Lilly and academic institutions.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	294	179	117	120	149
Cost of product sales	20	19	7	2	1
Research and development	33	23	25	—	—
Selling, general and administrative	116	113	106	112	92
Total costs and expenses	169	155	137	176	162
Income (loss) from operations	125	24	−20	−56	−12
Interest income	4	2	2	684,000	47,000
Interest expense	−7	−8	−7	—	—
Income (loss) before income taxes	122	18	−25	−59	−17
(Benefit from) provision for income taxes	−245	881,000	0	—	600,000
Net income (loss)	367	17	−25	−59	−18
Basic (in dollars per share)	20.4	0.99	−1.44	−3.44	−0.11
Diluted (in dollars per share)	19.48	0.99	−1.44	−3.44	−0.11
Basic (in shares)	18	18	17	17	170
Diluted (in shares)	19	18	17	17	170

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	41	57	33	24	19
Short-term investments	114	21	24	34	106
Accounts receivable, net	52	42	31	40	15
Inventories	12	6	6	9	7
Prepaid and other current assets	22	10	6	8	7
Total current assets	240	135	99	116	154
Intangible assets, net	25	27	14	15	—
Deferred income tax asset	246	0	—	—	—
Operating lease right-of-use assets	920,000	246,000	861,000	2	10
Other assets	2	2	3	640,000	974,000
Total assets	514	164	117	134	167
Accounts payable	7	3	7	23	4
Accrued compensation	12	10	9	9	11
Accrued research and development	6	4	4	8	10
Acquisition related liabilities	5	0	—	—	—
Revenue reserves and refund liability	28	26	16	12	8
Loans payable, net, current portion	30	7	7	—	—
Other current liabilities	11	12	4	5	14
Lease liabilities, current portion	614,000	285,000	692,000	1	10
Total current liabilities	99	63	53	65	64
Acquisition-related liabilities	0	5	—	—	—
Long-term portion of lease liabilities	395,000	0	285,000	972,000	759,000
Long-term portion of loans payable, net	22	52	52	39	20
Other long-term liabilities	0	40	40	42	53
Total liabilities	122	161	146	148	137
Commitments	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024	0	0	—	—	—
Common stock, $0.001 par value; 400,000,000 shares authorized; 18,310,934 and 17,710,216 shares issued and outstanding as of December 31, 2025 and 2024, respectively	18,000	18,000	17,000	174,000	172,000
Additional paid-in capital	1,414	1,393	1,379	1,369	1,354
Accumulated other comprehensive income	181,000	10,000	8,000	−153,000	−102,000
Accumulated deficit	−1,023	−1,390	−1,408	−1,382	−1,324
Total stockholders equity	391	3	−29	−14	30
Total liabilities and stockholders equity	514	164	117	134	167

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	367	17	−25	−59	−18
Stock-based compensation expense	13	12	9	12	9
(Gain) loss on sale and disposal of fixed assets	0	−79,000	266,000	−138,000	—
Depreciation and amortization	2	2	1	998,000	1
Deferred income tax benefit	−246	0	0	—	—
Release of cost share liability	−40	0	0	—	—
Net amortization of discount on short-term investments and term loans	−1	−709,000	−479,000	−63,000	287,000
Accounts receivable, net	−10	−11	10	−25	501,000
Inventories	−6	764,000	1	−2	−5
Prepaid and other current and non-current assets	−12	−3	2	−513,000	7
Right-of-use assets	−674,000	615,000	1	8	8
Accounts payable	4	−4	−366,000	4	41,000
Accrued compensation	2	1	−190,000	−2	1
Accrued research and development	1	560,000	−4	−3	5
Revenue reserves and refund liability	1	11	4	4	2
Other current and long-term liabilities	−285,000	5	−2	−5	—
Lease liability	724,000	−692,000	−1	−9	−9
Net cash provided by (used in) operating activities	76	31	−6	−74	6
Maturities of short-term investments	61	40	42	101	62
Purchases of short-term investments	−153	−35	−31	−29	−141
Capital expenditures	0	−36,000	0	−450,000	—
Payments for acquisition of intangible assets	0	−360,000	−15	—	—
Proceeds from sale of property and equipment	0	98,000	259,000	893,000	—
Net cash (used in) provided by investing activities	−92	4	−4	73	−80
Net proceeds from term loan financing	0	0	20	20	—
Principal payments of term loans	−8	0	0	—	—
Net proceeds from issuance of common stock from equity plans	8	2	1	2	5
Closing purchase price payment related to asset acquisition	0	−10	0	—	—
Cost share payments to a collaboration partner	0	−4	−3	−15	—
Net cash provided by (used in) financing activities	601,000	−12	18	7	63
Net (decrease) increase in cash, cash equivalents and restricted cash	−16	24	8	6	−11
Interest paid	7	7	6	2	2
Income taxes paid	1	331,000	81,000	—	—
Increase in right-of-use assets and lease liability	1	0	0	—	—
Acquisition-related liabilities	5	5	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is RIGEL PHARMACEUTICALS INC's CIK number?

RIGEL PHARMACEUTICALS INC's SEC CIK number is 0001034842 (1034842). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find RIGEL PHARMACEUTICALS INC's SEC filings?

All of RIGEL PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did RIGEL PHARMACEUTICALS INC last report earnings?

RIGEL PHARMACEUTICALS INC (RIGL) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001034842-26-000033). This is RIGEL PHARMACEUTICALS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is RIGEL PHARMACEUTICALS INC's most recent earnings 8-K?

RIGEL PHARMACEUTICALS INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001034842-26-000033. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View RIGEL PHARMACEUTICALS INC's latest earnings 8-K →
Look up any company's CIK number →